Transfection of cloned genes into cultured cells has allowed the identification of discrete DNA sequences which restrict the transcription of eucaryotic genes to particular cell types. This regulation appears to be exerted by sequiences just upstream of the transcription start site (reviewed in reference 36) and by regulatory elements such as enhancers (reviewed in references 25 and 40) . (50) .
Another approach in the investigation of tissue-specific regulation of gene transcription has been to study the expression of genes which have been integrated into the genome of developing organisms after microinjection of the genes into zygotes (reviewed in references 9 and 34). In the transgenic strains produced, the integration site and copy number of the exogenous gene are identical in all cells and gene expression may be assessed within all tissues at various developmental stages. Although it has been done (18) , the production of transgenic mammals can become tedious and expensive when a large number of constructs need to be analyzed to identify regulatory regions.
Embryonal carcinoma (EC) cells are cultured lines of multipotential mouse cells whose differentiation patterns closely resemble those of the normal embryo (11) and thus provide an alternative system to study early developmental processes. Genes can be transfected into EC cells, and the expression of the exogenous genes in the resulting transformed clones may be assessed in a variety of cell types. Thus, the EC system may combine some of the experimental * Corresponding author.
rigor of transgenic mice with the practical advantages of a cell culture system.
In this study, we used the P19 line of EC cells (29) . P19 cells can be induced to differentiate in vitro into different cell types depending on the drug used. After aggregation and treatment with retinoic acid (RA), P19 cells differentiate into neurons, glia, and fibroblastlike cells (23, 24) . Aggregates of P19 cells exposed to dimethyl sulfoxide (DMSO) differentiate into a different spectrum of cell types which includes cardiac muscle (6, 28, 44) . Since no continuous lines of cardiac muscle cells have been established, and since primary cultures of cardiac muscle can only be maintained with difficulty for short periods, the P19 cell system is unique for investigating gene expression during the de novo differentiation of cardiac muscle.
An isoform of actin, called cardiac actin, is synthesized exclusively in cardiac and embryonic skeletal muscle cells. We have transfected the human cardiac actin (CH-actin) gene into P19 cells and have found the gene expressed with appropriate developmental and cell type specificity.
MATERIALS AND METHODS P19 cell culture. The P19 cells were maintained and differentiated as described elsewhere (29, 38) . To induce differentiation,' cells were allowed to aggregate and were cultured in petri-grade culture dishes in the presence of 5 x i0' M RA (23) (7, 17) , along with 5.4 kb of 5'-flanking sequence, is contained within a 13-kb EcoRI fragment which was inserted into the EcoRI site of pSV2-neo (46) and called pNA8. A second plasmid was constructed (pNA-AI) with sequences upstream of a BamHI site removed, leaving 0.8 kb of flanking sequences upstream of the CH-actin transcription start site. (B) Relation of hybridization probes to the CH-actin gene. The 1.5-kb PstI 5' fragment was used as a specific probe to identify P19(CH-actin) transformants in Southern blot hybridization experiments, and the 0.45-kb HaeIII-PstI fragment was used as a cardiac actin isotype-specific probe in Northern blot hybridization experiments. The 0.6-kb Pstl fragment was used in nuclease S1 mapping experiments. --, Transcript;, coding exons; *, untranslated regions; UT, untranslated.
individually picked after 8 to 10 days of selection and expanded into cell lines in the absence of G418.
RNA purification and nuclease Si analysis. Cytoplasmic RNA was isolated by streptomycin precipitation (43) , whereas total RNA was isolated by the lithium chloride-urea extraction method (1) . The 600-base pair (bp) PstI 3' fragment (Fig. 1B) (27) . Nuclease S1 analysis was performed as described elsewhere (3, 49) . Briefly, RNA (20 ,ug) 1,000 U of S1 nuclease (Boehringer Mannheim Biochemicals) per ml was added to the hybridization mix, and digestion was allowed to proceed for 45 min at 45°C. The reaction was stopped by a phenol-chloroform extraction. The heteroduplexes were recovered by ethanol precipitation and suspended in loading buffer. The protected fragments were electrophoresed through 5% acrylamide-8 M urea sequencing gels and visualized by autoradiography.
Immunofluorescence. Immunofluorescence experiments were performed as described elsewhere (38) . Cells were grown directly on cover slips. Muscle myosin and muscle actin proteins were detected simultaneously by staining the fixed cells (15 min in -20°C methanol) with a mouse monoclonal antibody, MF20, which reacts with muscle myosin (2) and rabbit antiserum raised against an N-terminal peptide of skeletal actin (4) . To detect the herpes simplex virus thymidine kinase (HSV-TK) protein, cells were simultaneously stained with rabbit anti-TK antiserum (16) and with mouse monoclonal antibodies against either muscle myosin (MF20) or muscle actin (B4F8) (J. Lessard, personal communication). Second antibodies were fluorescein-conjugated antirabbit and rhodamine-conjugated anti-mouse immunoglobulins G.
RESULTS
Introduction of the CH-actin gene into P19 cells. Our strategy was to transfect the CH-actin gene into the P19 line of EC cells, obtain stable transformants, and determine whether the CH-actin gene was appropriately regulated when the transformed cells were induced to differentiate into cardiac muscle and nonmuscle cell types. The two plasmids used for transfection contained the neo gene, which confers resistance to the antibiotic G418 (45) , and the entire coding region of the CH-actin gene with either 5.4 (pNA8) or 0.8 (pNA-A1) kilobases (kb) of sequence upstream of the site of transcription initiation (Fig. 1A) .
Plasmids were introduced into P19 cells by the calcium phosphate precipitation method of DNA transfection (12 (Table 1) .
Developmental regulation of the CH-actin gene during cardiac muscle differentiation. We used a nuclease S1 mapping procedure to detect CH-actin mRNA in P19(CH-actin) transformants and to distinguish the CH-actin mRNA from transcripts originating from the endogenous mouse cardiac actin (CM-actin) gene. The 600-nucleotide (nt) probe used in these experiments spans the last exon of the CH-actin gene ( Fig.  1B and 2A ). The CH-actin mRNA protected a 330-nt fragment from nuclease S1 digestion (Fig. 2B , lane 6), whereas the CM-actin mRNA protected fragments of between 152 and 140 nt (Fig. 2B , lanes 1, 4, and 6). None of the mRNAs encoding other actin isoforms protected a labeled region of the probe (Fig. 2B , lanes 2, 3, and 5). CM-actin mRNA was readily detected in DMSO-treated P19 cultures (Fig. 2B , lanes 4 and 6), whereas no such transcript was detected in either EC cells or RA-treated cultures (Fig. 2B , lanes 3 and 5).
The levels of CH-actin mRNA during the development of cardiac muscle were examined to determine whether transcription of endogenous CM-actin and transfected CH-actin genes were subject to similar developmental regulation. The experiment was performed with cultures which consisted of (2) . ND, Not determined.
c The amount of CH-actin mRNA was determined by scintillation counting of nuclease Si-protected fragments cut out of the sequencing gel. The activity found in DMSO-treated cultures was divided by the activity found in EC cultures. NA, Not applicable. over 50 pooled clones of P19(CH-actin) cells transfected with the pNA-A1 plasmid. This approach was taken to obtain the average of a large number of transfected clones.
Spontaneously beating cardiac muscle and cells reactive with the muscle myosin-specific antibody, MF20 (2), first appeared on day 6. The CM-actin mRNA also became evident on day 6, increased rapidly to peak on day 7, and decreased slowly to about 30% of the maximum level by day 10 ( Fig. 3 ). This pattern of CM-actin expression was identical to that observed in untransfected DMSO-treated P19 cells.
A low level of CH-actin mRNA was present in Pl9(CH_ actin) cells, but this level decreased continuously during the first 5 days of the differentiation regime. The CH-actin mRNA level abruptly increased on day 6 in parallel with the appearance of the CM-actin transcript, peaked on day 7, and decreased thereafter (Fig. 3) . These results suggest that the transfected CH-actin gene was subject to the same regulatory mechanisms which control the developmental expression of the endogenous CM-actin gene.
Because the simian virus 40 (SV40) promoter drives the neo gene in the plasmid carrying the CH-actin gene, it was possible that the peak in CH-actin mRNA seen in Fig. 3 might be due to an effect of the SV40 enhancer. However, this seems very unlikely because the level of the neo mRNA actually decreased (by about twofold) during the course of DMSO-induced differentiation of transformed cells (data not shown).
In DMSO-induced differentiation experiments, only about 10% of the cells develop into cardiac muscle. To determine the level of CH-actin mRNA in differentiated nonmuscle cells, four fibroblastlike cell lines were isolated from cultures induced to differentiate with DMSO and their RNA was assessed for the presence of the CH-actin transcript. No CH-actin mRNA was detected in two of three clonal fibroblastlike cell lines derived from one of the Pl9(CH-actin) clones, P19AD43 (Fig. 4 ; compare lane 1 with lanes 2, 3, and 4). In a nonclonal fibroblastlike cell line derived from another clone, P19AD54, the CH-actin mRNA was present at a level much lower than that found in the parental EC cells (Fig. 4; The 600-bp PstI fragment containing the last coding exon (Ei) of the C -actin gene was 3' end labeled with T4 DNA polymerase, hybridized to RNA samples containing human and mouse C-actin mRNAs, and digested with nuclease S1. The CH-actin mRNA protects 330 nt, whereas the CM-actin mRNA protects a maximum of 152 nt of the 3' end of the probe (*, label). (B) RNA from mouse striated muscle and P19 cells subjected to nuclease S1 analysis. M, Size markers (indicated on the left in nucleotides) consisting of pAT153 digested with HpaII and 3' end labeled with T4 DNA polymerase; P, probe only; 1, mouse heart muscle; 2, mouse skeletal muscle; 3, undifferentiated P19 cells; 4, P19 cells induced to differentiate with DMSO into cultures which include cardiac muscle; 5, P19 cells induced to differentiate with RA into neurons, glia, and fibroblastlike cells; 6, P19AD32 after DMSO treatment. Probe, Human, and Mouse denote the 600-nt input probe, the 330-nt human protected fragment, and the 152-nt mouse protected fragment, respectively. in most of the nonmuscle cells, suggesting that both activating and repressing mechanisms are responsible for regulating the CH-actin promoter. (Table 1), the level of CH-actin mRNA was determined on day 10 although the peak level of expression was on day 7 ( Fig. 3) , and the level of CH-actin mRNA actually decreased in the nonmuscle cells within DMSO-treated cultures ( Fig. 3  and 4) .
The increase in CH-actin mRNA after DMSO treatment did not correlate with the proportion of muscle cells (Table  1) , probably because of the clone-to-clone variation in levels of CH-actin mRNA in EC cells. The level of CH-actin mRNA in EC cells was not related to the level of neo mRNA (data not shown) or to the copy number of the transfected gene (Table 1 ). In addition, the length of the upstream region (5.4 or 0.8 kb) flanking the CH-actin gene did not appear to affect the levels of CH-actin mRNA in EC cells or their differentiated derivatives (Fig. 5 and Table 1 ).
In the two cell lines, P19A24 and P19AD54, which carried more than 200 copies of the C -actin gene, only small amounts of CM-actin mRNA were present in DMSO-treated cultures containing relatively large amounts of muscle (Fig.  5, lanes 8 and 20) . Higher levels of the CM-actin mRNA were present after DMSO treatment of other cell lines, such as P19AD32, which developed similar amounts of muscle but which contained fewer copies of the CH-actin gene (Fig. 5 , lane 14; Table 1 ). These results suggest that the CM-actin and CH-actin genes may compete for limiting amounts of a transcription factor(s) in muscle cells.
Most RA-treated cultures of P19(CH-actin) cells contained lower levels of CH-actin mRNA than those found in the corresponding EC cells (Fig. 5, lanes 9, 15, 18, and 21) . Two exceptions were observed in the 10 transformants examined. The CH-actin mRNA was detectable only after RA treatment of P19A6 cells (Fig. 5, lane 6) , whereas the level of CH-actin mRNA increased after RA treatment of P19A35 cells (Fig. 5,  lane 12 these two lines may be a consequence of rearrangment of the transfected gene or its integration into a region of the genome influenced strongly by neighboring sequences.
Restriction of C'-actin protein to muscle cells. Detectable levels of CH-actin mRNA were present in some Pl9(CH_ actin) transformants and in some of their differentiated nonmuscle derivatives (Fig. 3 to 5 ). To determine whether the CH-actin mRNA was translated in these nonmuscle cells, we performed immunofluorescence experiments using a polyclonal antiserum which reacts with the cardiac and skeletal isoforms of actin protein (4) . In four clonal lines of transformants (P19A24, P19A35, P19AD43, and P19AD54), virtually no cardiac actin protein was detected in untreated and RA-treated cultures (Fig. 6, panels A through D) . Within DMSO-treated cultures, cardiac actin protein was not detected in cells that did not also contain muscle myosin (Fig.  6 , panels E through J). In addition, no cardiac actin protein was detected in the differentiated nonmuscle cells from the four fibroblastlike lines derived after DMSO treatment of P19AD43 and P19AD54 (data not shown). These experi- (B and C) Actin-tk and actin mRNAs were detected by Northern blot hybridization of total RNA isolated from P19(actin-tk) transformants to either TK-specific (B) or actin-specific (C) (0.6-kb PstI probe, Fig. 1B) probes. Shown here are two P19(actin-tk) clones. EC, D, and R, RNAs isolated from EC cells, DMSO-treated cultures, and RA-treated cultures, respectively. P19P106 but not P19P2 contained the actin-tk mRNA, other bands are due to nonspecific hybridization to rRNA. L6U3 is a rat cell line transformed with pPTK, which expresses high levels of actin-tk mRNA. ments suggest that the CH-actin protein is synthesized in nonmuscle cells at levels below the limits of detection of our immunofluorescence technique, that the CH-actin protein is not incorporated into microfilaments, that the CH-actin protein is rapidly degraded in nonmuscle cells, or that the CH_ actin mRNA is not efficiently translated in nonmuscle cells. Further support for the last possibility will be published separately (M. M. Ruben, M. A. Rudnicki, T. S. Bladon, K. Jardine, J. Craig, and M. W. McBurney, submitted for publication).
Muscle-specific expression of an actin-tk chimeric gene. The differentiation-dependent changes in the levels of CH-actin mRNA in P19(CH-actin) transformants were likely due to regulation of CH-actin gene transcription. To investigate the CH-actin gene promoter in more detail, we constructed a chimeric gene in which the CH-actin gene promoter (-700 to +740 bp from the transcription start site) was linked to the HSV tk) coding region (Fig. 7A) . The chimeric actin-tk gene was cotransfected with pSV2-neo (46) into P19 cells. G418-resistant clones were subsequently selected, and those containing the chimeric gene were identified by Southern blot hybridization (data not shown). Northern (RNA) blot analysis of P19(actin-tk) transformants indicated that in five independent clones, a low but detectable level of actin-tk mRNA was present in EC cultures and increased 3 to 13 times after DMSO treatment but not after RA treatment (Fig. 7B, lanes 5 to 7) . This increase in actin-tk mRNA coincided with the appearance of the FIG. 6 . Restriction of the cardiac actin protein to muscle cells in P19(CH-actin) transformants. Indirect immunofluorescence was used to determine the distribution of cardiac actin and skeletal actin proteins in P19AD43 cells. Both EC cells (panels A and B) and RA-treated cultures containing neurons, glia, and fibroblastlike cells (panels C and D) expressed some CH-actin mRNA (Fig. 5) but did not contain detectable cardiac actin protein (panels B and D). After DMSO treatment, the majority of myocytes were cardiac muscle (E) but some skeletal muscle was also apparent (H). The muscle cells contained muscle myosin (G and J) and cardiac actin and/or skeletal actin (F and I) proteins. A, C, E, and H are phase-contrast fields. B? D, E, and I are the corresponding fields stained with rabbit antiserum which reacts with cardiac actin and skeletal actin proteins (4) . G and J were stained with monoclonal antibody MF20 (2) reactive with muscle myosin. Second antibodies were fluorescein-conjugated anti-rabbit and rhodamine-conjugated anti-mouse immunoglobulins G. Bar, 50 p.m. 1.7-kb CM-actin transcript in DMSO-treated cultures (Fig.  7C, lane 6) . Many of the other P19(actin-tk) transformants did not express the chimeric gene under any conditions (Fig.  7B, lanes 2 to 4) .
The HSV-TK protein translated from the actin-tk mRNA in P19(actin-tk) transformants was detected by immunofluorescence by using a monospecific antibody (16) . The TK protein was located almost exclusively within the nuclei of cells which also contained muscle myosin (Fig. 8 , panels A through C) and cardiac or skeletal actin (Fig. 8 , panels D through F). Table 2 summarizes the results of these double staining experiments. In four P19(actin-tk) cell lines, over 86% of the muscle cells contained TK protein, whereas less than 2% of nonmuscle cells in DMSO-treated cultures (Table  2 ) and less than 0.1% of cells within EC cultures (data not shown) had detectable TK protein in their nuclei. These rare TK-containing cells within EC cultures may have spontaneously differentiated into muscle since they did not stain with anti-EC antibody (AEC3A1-9) and did stain with an antibody (B4F8) reactive with all forms of muscle actin.
Thus, the TK product of the actin-tk gene appeared almost exclusively in muscle cells, providing strong evidence for the muscle-specific activity of the CH-actin promoter after its stable integration into multipotential P19 cells.
DISCUSSION
In this study, we have transfected the CH-actin gene into multipotential P19 cells and isolated stable transformants. Transcripts from the CH-actin gene were present at a low level in undifferentiated EC cells and in some differentiated nonmuscle cells. However, a marked increase in the level of CH-actin mRNA occurred in parallel with transcripts from the endogenous CM-actin gene during cardiac muscle differentiation. In P19 cells transfected with the actin-tk chimeric gene, the TK protein was located almost exclusively in muscle cells. Thus, the DNA sequences which direct the muscle cell-specific expression of the CH-actin gene lie between -700 and +740 bp from the transcription start site. These results suggest that the changes in the level of CH-actin mRNA are due to an increase in the rate of transcription of the CH-actin gene in cardiac muscle cells.
The activity of the CH-actin gene promoter has been previously investigated after transient transfection or stable transformation of mouse and rat skeletal myoblast cell lines (31) . In cells with integrated copies of the CH-actin promoters, the level of transcript generated by this promoter either did not increase or increased modestly after differentiation of myoblasts into multinucleate myotubes (20, 30 ; Ruben et al., submitted). The failure of skeletal myoblasts to efficiently regulate the CH-actin promoter may be due to the relatively advanced developmental stage of the cell lines used. Alternatively, the regulation of the CH-actin promoter may be a multistep process which requires "programming" by a cell which is a precursor to the muscle lineage. If such programming is required for the developmental regulation of CHactin gene expression, the identification of the relevant regions of DNA will require the use of a developing biological system such as that described in this communication.
In EC cells and RA-treated cultures, transcription initiated from the CH-actin promoter generated low levels of transcripts, although no CM-actin mRNA was detected. This inappropriate activity of the C -actin promoter may be due to an effect of the vector sequences or to the proximity of the SV40 early promoter and enhancer used to drive the neo gene. A role for the SV40 enhancer seems unlikely, however, since this sequence does not function as a strong enhancer in undifferentiated EC cells (10) . A more likely explanation for the low level of CH-actin expression in EC cells derives from the presence in EC cells of a cellular product with ElA-like activity (22 Fig. 1A] , containing the 3' untranslated region) indicated that the CH-actin mRNA in EC and RAtreated cells was the expected size, 1.7 kb, and therefore was likely correctly initiated and processed. Since the cardiac actin protein can be incorporated into cytoskeletal structures in mouse L cells (15) , our failure to detect this protein in P19(CH-actin) transformants suggests that the CH-actin and actin-tk transcripts are only efficiently translated in muscle cells. More direct evidence for translational regulation will be reported elsewhere (Ruben et al., submitted).
Other tissue-specific genes have been transfected into mouse EC cells. Cloned globin and crystallin genes have been introduced into multipotential EC cells, but regulated expression could not be demonstrated, perhaps because the EC cells did not differentiate into those cell types expected to express high levels of the transfected genes (26, 35, 48) . The F9 cell line, which differentiates only into extraembryonic endodermal cells (47), has been transfected with H-2 (37) and alpha-fetoprotein (39) genes, and transcripts from these transfected genes did increase appropriately after transformed cells differentiated into endoderm.
The experiments reported here demonstrate that the transfected CH-actin and chimeric actin-tk genes were subject to appropriate developmental and tissue-specific regulation during differentiation of transfected P19 cells into cardiac muscle. Sequences located between -700 and +740 bp from the CH-actin transcription initiation site were able to mediate this muscle-specific regulation. Thus, transfected P19 cell cultures, like transgenic animals (8, 32, 33, 41, 42, 52) , are a suitable biological test system for identifying those DNA sequences responsible for muscle-specific gene expression.
